Back to Search Start Over

Association between 5-alpha reductase inhibition and risk of hip fracture.

Authors :
Jacobsen SJ
Cheetham TC
Haque R
Shi JM
Loo RK
Jacobsen, Steven J
Cheetham, T Craig
Haque, Reina
Shi, Jiaxiao M
Loo, Ronald K
Source :
JAMA: Journal of the American Medical Association. 10/8/2008, Vol. 300 Issue 14, p1660-1664. 5p.
Publication Year :
2008

Abstract

<bold>Context: </bold>For more than 15 years, 5-alpha reductase inhibitors, which block the conversion of testosterone to dihydrotestosterone, have been used in the treatment of benign prostatic hyperplasia (BPH). Short-term studies show no effects of these agents on bone metabolism,but long-term data are not available.<bold>Objective: </bold>To assess the association between use of 5-alpha reductase inhibitors (eg, finasteride) for BPH and occurrence of hip fracture.<bold>Design, Setting, and Patients: </bold>Population-based case-control study using data from Kaiser Permanente Southern California, a managed care organization with more than 3 million members. Case patients included 7076 men 45 years and older with incident hip fracture from 1997-2006. Control patients were 7076 men without incident hip fracture, optimally matched at a 1:1 ratio to case patients on age and medical center. Electronic information on pharmaceutical use was used to identify use of finasteride from 1991 forward.<bold>Results: </bold>Overall, 2547 (36%) and 2488 (35%) case and control patients, respectively, had a diagnosis of BPH (P = .30), and 109 (1.5%) and 141 (2.0%) of case and control patients, respectively, had been exposed to finasteride prior to the index date (matched odds ratio, 0.77; 95% confidence interval, 0.59-1.00; P = .04). There was no suggestion of a dose-response relationship between exposure to 5-alpha reductase inhibitors when the exposure was stratified into tertiles of total exposure (P = .12). By contrast, there was a slightly higher prevalence of alpha-blocker use in case vs control patients (32% vs 30%, respectively; P = .04).<bold>Conclusions: </bold>Exposure to 5-alpha reductase inhibitors was not associated with increased risk of hip fracture. The reduction in risk observed with exposure to 5-alpha reductase inhibitors and the modest increase in risk associated with exposure to alpha-blockers require replication and warrant further investigation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00987484
Volume :
300
Issue :
14
Database :
Academic Search Index
Journal :
JAMA: Journal of the American Medical Association
Publication Type :
Academic Journal
Accession number :
105473383
Full Text :
https://doi.org/10.1001/jama.300.14.1660